BioSpace News Archive

The global formulation development outsourcing market size was estimated at around USD 31.1 billion in 2021 and it is projected to hit around USD 61.6 billion by 2030, growing at a CAGR of 7.89% from 2022 to 2030.

Diabetes Research Connection, a 501 that funds research projects conducted by early-career researchers aimed at prevention, cure, and better care for those with Type 1 Diabetes, recently awarded seed funding to eight promising new T1D studies totaling a $400,000 investment, as it celebrates 10 years advancing diabetes research.

Zhittya Genesis Medicine, Inc., announced that the human test subjects in its first-in-human research study for the treatment of Parkinson’s disease, at the 30 interim examination had a 50% improvement in their motor skills.

MCRA, LLC, a leading medical device and biologics advisory firm and clinical research organization (CRO) integrating U.S. and International Regulatory, Clinical Research, Reimbursement, Healthcare Compliance, Quality Assurance, and Cybersecurity is pleased to announce its role in the granting of the DeNovo by the U.S. Food and Drug Administration (FDA) for BONESUPPORT’S CERAMENT G.

LAVA Therapeutics N.V. hosted a clinical update call focused on encouraging initial Phase 1/2a clinical data for LAVA-051 in patients with chronic lymphocytic leukemia and multiple myeloma patients following poster presentations at the 2022 American Society of Clinical Oncology Annual Meeting held June 3-7, 2022, and the European Hematology Association 2022 Congress, held June 9-12, 2022.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide), a melanocortin-4 receptor (MC4R) agonist, for patients with Bardet-Biedl syndrome (BBS).

Vaxart, Inc. announced that it will host a question-and-answer webcast with investors and analysts on Wednesday, June 22, 2022, at 1:00 p.m. Eastern Time.

Profound Medical Corp. announced that its CEO and Chairman, Arun Menawat, will participate in a virtual panel discussion on Focused Ultrasound hosted by Joshua Jennings, M.D., Managing Director, Health Care - Medical Supplies & Devices, at Cowen’s 7th Annual FutureHealth Conference on Thursday, June 23, 2022 at 9:55 a.m. Eastern Time.

Rapid Dose Therapeutics Corp. announces that it will not be in a position to file its audited annual financial statements for the fiscal year ended February 28, 2022, including the related management’s discussion and analysis and CEO and CFO certifications by the filing deadline of June 28, 2022.

A new research report titled “Global Anti-hyperlipidemic Agents market” successfully exhibits the complete scenario of the global and an individual analysis of the various regional segments.